Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Return on Sales: 2018-2025

Historic Return on Sales for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Sep 2025 value amounting to 131.27%.

  • Rocket Pharmaceuticals' Return on Sales fell 1117.00% to 131.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 131.27%, marking a year-over-year decrease of 1117.00%. This contributed to the annual value of 141.48% for FY2024, which is 481.00% up from last year.
  • Rocket Pharmaceuticals' Return on Sales amounted to 131.27% in Q3 2025, which was down 6.35% from 140.17% recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Return on Sales ranged from a high of 142.44% in Q3 2024 and a low of 21.68% during Q1 2021.
  • Moreover, its 3-year median value for Return on Sales was 139.75% (2023), whereas its average is 137.90%.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Return on Sales skyrocketed by 7,734bps in 2022 and then plummeted by 1,117bps in 2025.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Return on Sales stood at 56.15% in 2021, then surged by 6,331bps to 119.46% in 2022, then surged by 1,720bps to 136.66% in 2023, then soared by 481bps to 141.48% in 2024, then plummeted by 1,117bps to 131.27% in 2025.
  • Its Return on Sales stands at 131.27% for Q3 2025, versus 140.17% for Q2 2025 and 140.72% for Q1 2025.